Alkylphosphocholines: A new therapeutic option in glaucoma filtration surgery

Investigative Ophthalmology and Visual Science

Volumn 45, Issue 8, 2004, Pages 2619-2624

  Eibl, Kirsten H ^a   Banas, Bernhard ^b   Kook, Daniel ^a   Ohlmann, Anne V ^a   Priglinger, Siegfried ^a   Kampik, Anselm ^a   Welge Luessen, Ulrich C ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINE DERIVATIVE; COLLAGEN GEL; PHOSPHORYLCHOLINE; PROTEIN KINASE C; TETRAZOLIUM; TRYPAN BLUE;

ARTICLE; CASE REPORT; CELL MIGRATION; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVITY; FETAL CALF SERUM; FIBROBLAST; FILTERING OPERATION; GLAUCOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IC 50; PRIORITY JOURNAL; REDUCTION;

ADULT; CELL DIVISION; CELL MOVEMENT; CELLS, CULTURED; COLLAGEN; ENZYME INHIBITORS; FIBROBLASTS; FIBROSIS; FILTERING SURGERY; GLAUCOMA; HUMANS; MALE; MIDDLE AGED; PHOSPHORYLCHOLINE; PROTEIN KINASE C;

EID: 3242879408     PISSN: 01460404     EISSN: None     Source Type: Journal    
DOI: 10.1167/iovs.03-1351     Document Type: Article

References (49)

1. AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS) 7: the relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol. 2000;130:429-440.
2. Migdal C, Gregory W, Hitchings R. Long-term functional outcome after early surgery compared with laser and medicine in open-angle glaucoma. Ophthalmology. 1994;101:1651-1656.
3. The Fluouracil Filtering Surgery Study Group. Five-year follow-up of the Fluouracil Filtering Surgery Study Group. Am J Ophthalmol. 1996;121:349-366.
4. Mead AL, Wong TTL, Cordeiro MF, Anderson IK, Khaw PT. Evaluation of anti-TGF-beta2 antibody as a new postoperative anti-scarring agent in glaucoma surgery. Invest Ophthalmol Vis Sci. 2003;44:3394-3401.
5. Khaw PT, Occleston NL, Schultz G, Grierson I, Sherwood MB, Larkin G. Activation and suppression of fibroblast function. Eye. 1994;8:188-195.
6. Doyle JW, Sherwood MB, Khaw PT, McGrory S, Smith MF. Intraoperative 5-fluouracil for filtration surgery in the rabbit. Invest Ophthalmol Vis Sci. 1993;34:3313-3319.
7. Khaw PT, Ward S, Porter A. The long-term effects of 5-fluouracil and sodium butyrate on human Tenon's fibroblasts. Invest Ophthalmol Vis Sci. 1992;33:2043-2052.
8. Khaw PT, Doyle JW, Sherwood MB, Smith MF, McGorray S. Effects of intraoperative 5-fluouracil or mitomycin C on glaucoma filtration surgery in the rabbit. Ophthalmology. 1993;100:367-372.
9. Jampel HD, Pasquale LR, Dibernardo C. Hypotony maculopathy following trabeculectomy with mitomycin C. Arch Ophthalmol. 1992;110:1049-1050.
10. Khaw PT, Doyle JW, Sherwood MB, Grierson I, Schultz G, McGorray S. Prolonged localized tissue effects from 5-minute exposures to fluouracil and mitomycin C. Arch Ophthalmol. 1993;111:263-267.
11. Lamping KA, Belkin JK. 5-Fluouracil and mitomycin C in pseudophakic patients. Ophthalmology. 1995;102:70-75.
12. Parrish R, Minckler D. "Late endophthalmitis": filtering surgery time bomb? Ophthalmology. 1996;103:1167-1168.
13. Stamper RL, McMenemy MG, Lieberman MF. Hypotonus maculopathy after trabeculectomy with subconjunctival 5-fluouracil. Am J Ophthalmol. 1992;114:544-553.
14. Occleston NL, Daniels JT, Tamuzzer RW, et al. Single exposures to antiproliferatives: long-term effects on ocular fibroblast wound-healing behavior. Invest Ophthalmol Vis Sci. 1997;38:1998-2007.
15. Shin DH, Juzych MS, Khatana AK, Swendris RP, Parrow KA. Needling revision of failed filtering blebs with adjunctive 5-fluouracil. Ophthalmic Surg. 1993;24:242-248.
16. Katz GJ, Higginbotham EJ, Lichter PR, et al. Mitomycin C versus 5-fluouracil in high-risk glaucoma filtration surgery: extended follow-up. Ophthalmology. 1995;102:1263-1269.
17. Allen LE, Manuchehri K, Corridan PG. The treatment of encapsulated trabeculectomy blebs in an out-patient setting using a needling technique and subconjunctival 5-fluouracil injection. Eye. 1998;12:119-123.
18. Rothmann RF, Liebermann JM, Ritch R. Low-dose 5-fluouracil trabeculectomy as initial surgery in uncomplicated glaucoma: long-term follow-up. Ophthalmology. 2000;107:1184-1190.
19. Cordeiro MF, Gay JA, Khaw PT. Human anti-transforming growth factor-beta2 antibody: a new glaucoma anti-scarring agent. Invest Ophthalmol Vis Sci. 1999;40:2225-2234.
20. Siriwardena D, Khaw PT, King AJ, et al. Human anti-transforming growth factor beta2 monoclonal antibody: a new modulator of wound healing in trabeculectomy. Ophthalmology. 2002;109:427-431.
21. Wimmer I, Grehn F. Control of wound healing after glaucoma surgery: effect and inhibition of the growth factor TGF-beta. Ophthalmologe. 2002;99:678-682.
22. Hilgard P, Engel J. Clinical aspects of miltefosine and its topical formulation Miltex®. Drugs Today. 1994;30(suppl B):3-81.
23. Leonard R, Hardy J, van Tienhoven G, et al. Randomized, double-blind, placebo-controlled, multicenter trial of 6% miltefosine solution, a topical chemotherapy in cutaneous metastases from breast cancer. J Clin Oncol. 2001;21:4150-4159.
24. Eibl KH, Banas B, Schoenfeld CL, et al. Alkylphosphocholines inhibit proliferation of human retinal pigment epithelium. Invest Ophthalmol Vis Sci. 2003;44:3556-3561.
25. Shoji M, Raynor RL, Fleer EAM, Eibl H, Vogler WR, Kuo JF. Effects of hexadecylphosphocholine on protein kinase C and TPA-induced differentiation of HL60 cells. Lipids. 1991;26:145-149.
26. Überall F, Oberhuber H, Maly K, Zaknun J, Demuth L, Grunicke HH. Hexadecylphosphocholine inhibits inositol phosphate formation and protein kinase C activity. Cancer Res. 1991;51:807-812.
27. Engelmann J, Henke J, Wilker W. Early stages monitoring of miltefosine induced apoptosis in KB cells by multinuclear NMR spectroscopy. Anticancer Res. 1996;16:1429-1440.
28. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 1983;65:55-57.
29. Wuyts A, Menten P, Van Osselaer N, Van Damme J. Assays for chemotaxis. Methods Mol Biol. 2003;249:153-166.
30. Mazure A, Grierson I. In vitro studies of the contractility of cell types involved in proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci. 1992;33:3407-3416.
31. Occleston NL, Alexander RA, Mazure A, Larkin G, Khaw PT. Effects of single exposures to antiproliferative agents on ocular fibroblast-mediated collagen contraction. Invest Ophthalmol Vis Sci. 1994;35:3681-3690.
32. Bell E, Ivarsson B, Merrill C. Production of a tissue-like structure by contraction of collagen lattices by human fibroblasts of different proliferative potential in vitro. Proc Natl Acad Sci USA. 1979;76:1274-1279.
33. Chen SJ, Klann E, Gower MC, Powell CM, Sessoms JS, Sweatt JD. Studies with synthetic peptide substrates derived from the neuronal protein neurogranin reveal structural determinants of potency and selectivity for protein kinase C. Biochemistry. 1993;32:1032-1039.
34. Goueli BS, Hsiao K, Tereba A, Goueli SA. A novel and simple method to assay the activity of individual protein kinases in a crude tissue extract. Anal Biochem. 1995;225:10-17.
35. Bradford MM. A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976;72:248-252.
36. Erdlenbruch B, Jendrossek V, Gerriets A, Vetterlein F, Eibl H, Lakomek M. Erucylphosphocholine: pharmacokinetics, biodistribution and CNS-accumulation in the rat after intravenous administration. Cancer Chemother Pharmacol. 1999;44:484-490.
37. Sobottka SB, Berger MR, Eibl H. Structure-activity relationships of four anticancer alkylphosphocholine derivatives in vitro and in vivo. Int J Cancer. 1993;53:418-425.
38. Sundar S, Jha TK, Thakur CP, et al. Oral miltefosine for Indian visceral leishmaniasis. N Engl J Med. 2002;347:1739-1746.
39. Kotting J, Berger MR, Unger C, Eibl H. Alkylphosphocholines: influence of structural variation on biodistribution at antineoplastically active concentrations. Cancer Chemother Pharmacol. 1992;30:105-112.
40. Erdlenbruch B, Jendrossek V, Marx M, Hunold A, Eibl H, Lakomek M. Antitumor effects of erucylphosphocholine on brain tumor cells in vitro and in vivo. Anticancer Res. 1998;18:2551-2557.
41. Erdlenbruch B, Jendrossek V, Kugler W, Eibl H, Lakomek M. Increased delivery of erucylphosphocholine to C6 gliomas by chemical opening of the blood-brain barrier using intracarotid pentylglycerol in rats. Cancer Chemother Pharmacol. 2002;50:299-304.
42. Wong TT, Mead AL, Khaw PT. Matrix metalloproteinase inhibition modulates postoperative scarring after experimental glaucoma filtration surgery. Invest Ophthalmol Vis Sci. 2003;44:1097-1103.
43. Schlotzer-Schrehardt U, Lommatzsch J, Kuchle M, Konstas AG, Naumann GO. Matrix metalloproteinases and their inhibitors in aqueous humor of patients with pseudoexfoliation syndrome/glaucoma and primary open-angle glaucoma. Invest Ophthalmol Vis Sci. 2003;44:1117-1125.
44. Sakamoto T, Hinton DR, Sakamoto H, et al. Collagen gel contraction induced by retinal pigment epithelial cells and choroidal fibroblasts involves the protein kinase C pathway. Curr Eye Res. 1994;13:451-459.
45. Tan SL, Parker PJ. Emerging and diverse roles of PKC in immune cell signaling. Biochem. J 2003;276:345-352.
46. Becker KP, Hannun YA. CPKC-dependent sequestration of membrane recycling components in a subset of recycling endosomes. J Biol Chem. 2003;278:747-754.
47. Cordeiro MF, Bhattacharya SS, Schultz GS, Khaw PT. TGF-beta1, -beta2, and -beta3 in vitro: biphasic effects on Tenon's fibroblast contraction, proliferation, and migration. Invest Ophthalmol Vis Sci. 2000;41:756-763.
48. Tripathi RC, Li J, Borisuth NS, Tripathi BJ. Trabecular cells of the eye express messenger RNA for transforming growth factor-beta 1 and secrete this cytokine. Invest Ophthalmol Vis Sci. 1993;34:2562-2569.
49. Picht G, Welge-Luessen U, Grehn F, Lütjen-Drecoll E. Transforming growth factor beta 2 levels in the aqueous humor in different types of glaucoma and the relation to filtering bleb development. Graefes Arch Clin Exp Ophthalmol. 2001;239:199-207.